• HyperMed has assembled a highly experienced team of medical device professionals to commercialize its hyperspectral imaging technology.

Management

Mark Darty

Mark Darty

CEO and President

BIO

Max Mortensen, PhD

Max Mortensen, PhD

VP Regulatory Compliance and Quality Assurance

BIO

Peter Meenen, PhD

Peter Meenen, PhD

Director of R&D
and Chief Engineer

BIO

David Gaines

David Gaines

Director of Operations

BIO


Board of Directors

David Wetherell

David Wetherell

Managing Partner,
Biomark Capital

BIO

Douglas Lind, MD

Douglas Lind, MD

Managing Director,
Biomark Capital

BIO

Jay Fik

Jay Fik

Chief Investment Officer,
D. Canale & Co.

BIO

Mark Darty

Mark Darty

CEO and President, HyperMed Imaging, Inc.

BIO

HyperMed’s new tissue oximetry device called HyperView™ is FDA 510(k) cleared.
HyperMed, HyperView, OxyVu™-1 and the company logo are trademarks of HyperMed Imaging, Inc.